Cyclophosphamide cardiotoxicity

descriptionPublicationkeyboard_double_arrow_right Article 01 Jun 1980 English Publisher:Springer Science and Business Media LLCJournal:European Journal of Pediatrics, volume 134, pages 87-90 (issn: 0340-6199, eissn: 1432-1076,

Copyright policy )

Authors: G, von Bernuth; D, Adam; R, Hofstetter; D, Lang; W, Mohr; E, Kohne; D, Niethammer;

doi: 10.1007/bf00442410

pmid: 6997053

Cyclophosphamide cardiotoxicity

- Summary
- Subjects
- Metrics

Abstract

A 12-year-old boy with aplastic anemia developed severe but reversible cardiac failure after treatment with 200 mg/kg cyclophosphamide (4 x 50 mg/kg on four consecutive days) given as preparation for bone marrow grafting. This and previously reported cases demonstrate the possibility of cardiotoxicity after high doses of the drug.

Related Organizations

University of Ulm
Germany

Keywords

Heart Failure, Male, Anemia, Aplastic, Humans, Transplantation, Homologous, Child, Cyclophosphamide, Bone Marrow Transplantation

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	27
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%